BRISBANE, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced publication of CareDx’s AlloSure® validation study in The Journal of Molecular Diagnostics.
CareDx realizes that significant unmet needs exist for non-invasive diagnostic tools to monitor transplant recipients, especially for early detection of active injury and rejection as well as monitoring of changes in immunosuppressive therapy. For years the company has worked on providing novel diagnostic surveillance solutions for recipients of solid organ transplants.
The Journal of Molecular Diagnostics chose to highlight CareDx’s AlloSure assay, a new clinical grade non-invasive NGS test that measures donor-derived cell-free DNA (dd-cfDNA) in plasma, by featuring the study in a news release for the November issue of the journal.
“We greatly appreciate that the rigorous and comprehensive description of AlloSure’s validation is recognized by the molecular pathology community. Our team at CareDx has been working tirelessly on making this happen. With the data presented in heart transplant patients and additional data that we generated on kidney transplant patients, we believe we can significantly impact transplant patient care in the near future,” stated John J. Sninsky PhD, Chief Science Officer, CareDx, Inc.
The report has been posted on the JMD website on the press release page at http://jmd.amjpathol.org/content/press. The link to the article is http://jmd.amjpathol.org/article/S1525-1578(16)30138-6/fulltext.
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit: www.CareDx.com.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements including, but not limited to statements regarding the Company’s expectations regarding the effect of possible CMS decisions on the Company’s financial results and commercial operations. Forward looking statements are subject to uncertainties that could cause actual performance or results to differ materially from those expressed in the forward looking statements, including the Company’s ability to enter new businesses or other geographies if it is forced to discontinue AlloMap testing in the United States. CareDx disclaims any obligation to publicly update or revise any forward looking statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Investor Contact Jamar Ismail, Westwicke Partners T: +1 415-513-1282 firstname.lastname@example.org